Sensorion Refocuses on SENS-601 for Gene Therapy

Sensorion announces a strategic refocusing on the development of SENS-601, targeting hearing loss linked to the GJB2 gene. Clinical trial applications have been submitted in Canada and France, with Fast Track approval granted by the ANSM (French National Agency for Medicines and Health Products Safety). A Drug Facts Application (DNA) submission in the United States and Australia is planned by the end of 2026.

The SENS-601 program, in collaboration with the Pasteur Institute, could represent a major breakthrough in the treatment of genetic deafness. However, the company is halting development of SENS-501 to redirect its resources to SENS-601, deeming this program a priority due to the lack of available therapies for this significant unmet medical need.